Homology Medicines, Inc. (FIXX) News
Filter FIXX News Items
FIXX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FIXX News Highlights
- For FIXX, its 30 day story count is now at 3.
- Over the past 5 days, the trend for FIXX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about FIXX are GENE and GTX.
Latest FIXX News From Around the Web
Below are the latest news stories about HOMOLOGY MEDICINES INC that investors may wish to consider to help them evaluate FIXX as an investment opportunity.
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting- New Preclinical Data Demonstrated Ability to Re-Dose with AAVHSCs Across Viral Clades, Potentially Expanding Possibilities of Genetic Medicine Programs in the Future - - Presented Methods to Accelerate Identification of Genomic Sites that Result in Improved Homologous Recombination-Based Gene Editing Efficiency - BEDFORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today six presentations supporting its gene editing, g |
Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue EstimatesHomology Medicines (FIXX) delivered earnings and revenue surprises of 9.09% and 40.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights- On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 - - First Presentations of Preclinical Data with GTx-mAb Development Candidate HMI-104 for PNH, and Potential for Re-Dosing with AAVHSCs, at Upcoming ASGCT Meeting - - Solid Financial Position with Anticipated Cash Runway into Fourth Quarter 2024 - BEDFORD, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for t |
Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency - BEDFORD, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH). These data demonstrated that a one-time ad |
BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last?BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics MeetingBEDFORD, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced two presentations during the ACMG Annual Clinical Genetics Meeting, which highlight the preclinical data that supported initiation of the Company’s Phase 1 pheEDIT gene editing trial for phenylketonuria (PKU) and the Phase 1 juMPStart gene therapy trial for Hunter syndrome (MPS II). Additionally, the presentations feature trial design, including the targeted immunosu |
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue EstimatesHomology Medicines (FIXX) delivered earnings and revenue surprises of -17.65% and 23.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights- On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Year with First Participant Dosed and Others in Screening - - Initial Clinical Data from Gene Therapy Trial for Hunter Syndrome Anticipated in Second Half of 2023; Trial Recruiting in the U.S. and Canada - - Anticipated Cash Runway Into Fourth Quarter 2024 Enables Execution Against Key Milestones - BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, |
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical OfficerBEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical Officer. Previously, Dr. Jordan held the role of Senior Vice President, Head of Clinical Development and Operations, at Homology, and she has been instrumental in advancing Homology’s gene editing and gene therapy clinical programs. Under her leadership, Homology is conducting the pheEDIT trial for phe |
Homology Medicines to Participate in the 43rd Annual Cowen Healthcare ConferenceBEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the “Gene Editing Corporate Panel” during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET. The live webcast presentation will be accessible on Homology’s website in the Investors section, and the webcast replay will be available on the |